New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. (Q38026787)

27 August 2017

New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. (English)

1 reference

27 August 2017

0 references

Daniel J Wallace

1

1 reference

27 August 2017

Vineet S Gudsoorkar

series ordinal

2

1 reference

27 August 2017

Michael H Weisman

series ordinal

3

1 reference

27 August 2017

Swamy R Venuturupalli

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

17 July 2012

1 reference

Nature Reviews Rheumatology

27 August 2017

1 reference

27 August 2017

8

1 reference

27 August 2017

9

1 reference

27 August 2017

522-533

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2012.106

27 August 2017

0 references

cites work

DrugBank 3.0: a comprehensive resource for 'omics' research on drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Occasional series: lupus around the world systemic lupus erythematosus research in the Asia-Pacific region: a co-ordinated and co-operative approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Hydroxychloroquine and retinal safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Antimalarials--the 'real' advance in lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Features of systemic lupus erythematosus in Dnase1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Toll-like receptors in systemic autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Intracellular toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

The natural interferon-alpha producing cells in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Direct evidence that toll-like receptor 9 (TLR9) functionally binds plasmid DNA by specific cytosine-phosphate-guanine motif recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

A Toll-like receptor 9-mediated pathway stimulates perilipin 3 (TIP47) expression and induces lipid accumulation in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Thematic review series: The immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Biochemical characterization of ADP-ribose polymer metabolism in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Predictors of major infections in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Relation between markers of systemic vascular inflammation and smoking in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Cigarette smoking and cutaneous damage in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Impact of smoking in cutaneous lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Antimalarial drugs and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Hydroxychloroquine in lupus pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Advances in drug therapy for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Tissue and blood concentrations of chloroquine following chronic administration in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

The type I interferon system in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

The type I interferon system in the development of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Comparison of effects of two antimalarial agents, hydroxychloroquine sulfate and chloroquine phosphate, in patients with rheumatoid arthitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Absorption of antimalarial drugs in human skin; spectroscopic and chemical analysis in epidermis and corium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

Mechanism of action of hydroxychloroquine as an antirheumatic drug

31 March 2020

1 reference

12 December 2020

Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment

1 reference

12 December 2020

Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes

1 reference

12 December 2020

Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.

1 reference

12 December 2020

Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds.

1 reference

12 December 2020

Quinacrine but not chloroquine inhibits PMA induced upregulation of matrix metalloproteinases in leukocytes: quinacrine acts at the transcriptional level through a PLA2-independent mechanism.

1 reference

12 December 2020

The history of antimalarials.

1 reference

12 December 2020

Reconsidering antimalarials in systemic lupus erythematosus: developments of translational clinical interest

1 reference

12 December 2020

Non-methylated CpG-rich islands at the human alpha-globin locus: implications for evolution of the alpha-globin pseudogene

1 reference

12 December 2020

Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.

1 reference

12 December 2020

Matrix metalloproteinases and their inhibitors in connective tissue remodeling

1 reference

12 December 2020

Hydroxychloroquine Effects on Lipoprotein Profiles (the HELP trial): A Double-Blind, Randomized, Placebo-Controlled, Pilot Study In Patients With Systemic Lupus Erythematosus.

1 reference

12 December 2020

The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus

1 reference

12 December 2020

Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy

1 reference

12 December 2020

Hydroxychloroquine in pregnant patients with systemic lupus erythematosus

1 reference

12 December 2020

Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus

1 reference

12 December 2020

The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus

1 reference

12 December 2020

Inhibition of proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339

1 reference

12 December 2020

Cholesterol homeostasis is modulated by amphiphiles at transcriptional and post-transcriptional loci

1 reference

12 December 2020

Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.

1 reference

12 December 2020

Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

7 January 2021

inferred from DOI database lookup

Mechanism of action of hydroxychloroquine as an antirheumatic drug

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.106

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NRRHEUM.2012.106

1 reference

Dimensions Publication ID

27 August 2017

1030064389

0 references

Fatcat ID

release_kpwqlprcpngmbiwriwufu5q5qi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kpwqlprcpngmbiwriwufu5q5qi

24 November 2022

mapped directly with Wikidata item

1 reference